Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
This study found cefiderocol was non-inferior to imipenem-cilastatin for the primary endpoint (composite of clinical and microbiological outcomes 7 days after treatment cessation; 73% vs 55%, respectively; adjusted treatment difference 18.58%, 95% CI 8.23-28.92; p=0.0004)
CONCLUSION: Our findings showed that the majority of patients hospitalized in different wards of hospitals have experienced the urinary tract infection caused by P. aeruginosa. According to the genotyping results, a high diversity of the P. aeruginosa population was observed in the patients with UTI. Our results can provide a better understanding of the P. aeruginosa genotype distribution and epidemiology of infection, which can be applied as basic data for future antibiotic therapies. PMID: 31300119 [PubMed - in process]
Urology Annals 2019 11(3):338-338
ConclusionThis is the first HAI PPS to be conducted in Australia in 34 years. The prevalence rate is higher than the previous Australian study and that reported by the ECDC, however differences in methodology limit comparison. Regular, large scale HAI PPS should be undertaken to generate national HAI data to inform and drive national interventions.
This study is registered with ClinicalTrials.gov, number NCT03461757, and is closed to accrual.FindingsBetween Feb 27 and Aug 28, 2018, 1811 participants were recruited and assessed for eligibility. 1466 participants were randomly assigned to the rimegepant (n=732) or placebo (n=734) groups, of whom 1375 received treatment with rimegepant (n=682) or placebo (n=693), and 1351 were evaluated for efficacy (rimegepant n=669, placebo n=682). At 2 h postdose, rimegepant orally disintegrating tablet was superior to placebo for freedom from pain (21% vs 11%, p
As the infections become increasingly resistant to antibiotics, some standard treatments no longer work for an ailment that was once easily cured.
U.T.I.s are one of the world ’s most common infections but many of the drugs used to treat them have become less effective as resistance to antibiotics grows.
CONCLUSION: The recognition of E. coli captured by phagosomes or partially damaged by lysosomal attack within the cell was recorded for the first time. Furthermore, SEM observation was performed on human tissue. PMID: 31298302 [PubMed - as supplied by publisher]
ConclusionThis is the first study specifically examining the teratogenic risk of fosfomycin. The study results do not indicate an increased risk of adverse pregnancy outcome after fosfomycin exposure during early pregnancy. However, larger studies are needed to confirm the safety of fosfomycin during the first trimester.